Ocugen is trading 7.97% higher at MXN 18.43, as its scheduled OCU410ST Phase 1 data presentation may be drawing attention. - Ocugen is scheduled to present safety and tolerability data at the Retina Society meeting on September 23, 2026; no results were available in the reviewed coverage. - No confirmed company-specific announcement explaining the move was identified. - The broader biotech sector is also higher, providing supportive context.